PT1850873T - Anticorpos contra tgfbeta - Google Patents

Anticorpos contra tgfbeta

Info

Publication number: PT1850873T
Authority: PT; Portugal
Prior art keywords: tgfbeta; antibodies
Prior art date: 2005-02-08

Application number

PT06734583T

Other languages

English (en)

Inventor

G Holgate Robert

R Ledbetter Steven

P Hart Celia

U Jermutus Lutz

L Buchanan Catriona

R Duncan Alexander

K Finch Donna

Original Assignee

Genzyme Corp

Optein Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-08

Filing date

2006-02-08

Publication date

2019-02-19

2006-02-08 Application filed by Genzyme Corp, Optein Inc filed Critical Genzyme Corp

2019-02-19 Publication of PT1850873T publication Critical patent/PT1850873T/pt

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT06734583T 2005-02-08 2006-02-08 Anticorpos contra tgfbeta PT1850873T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US65134305P	2005-02-08	2005-02-08

Publications (1)

Publication Number	Publication Date
PT1850873T true PT1850873T (pt)	2019-02-19

Family

ID=36793677

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT182083824T PT3520815T (pt)	2005-02-08	2006-02-08	Anticorpos contra tgfbeta
PT06734583T PT1850873T (pt)	2005-02-08	2006-02-08	Anticorpos contra tgfbeta

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT182083824T PT3520815T (pt)	2005-02-08	2006-02-08	Anticorpos contra tgfbeta

Country Status (19)

Country	Link
US (11)	US7723486B2 (pt)
EP (2)	EP1850873B1 (pt)
JP (5)	JP5174466B2 (pt)
CN (3)	CN101163502A (pt)
AU (1)	AU2006213875B2 (pt)
BR (1)	BRPI0607639B1 (pt)
CA (2)	CA2930677A1 (pt)
CY (1)	CY1121424T1 (pt)
DK (1)	DK1850873T3 (pt)
ES (2)	ES2711213T3 (pt)
HU (1)	HUE042689T2 (pt)
IL (3)	IL184995A (pt)
LT (1)	LT1850873T (pt)
MX (1)	MX2007009545A (pt)
PL (2)	PL3520815T3 (pt)
PT (2)	PT3520815T (pt)
SI (1)	SI1850873T1 (pt)
TR (1)	TR201901929T4 (pt)
WO (1)	WO2006086469A2 (pt)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2607422Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
JP2607424Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
JP2607423Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
JP2607425Y2 (ja)	1990-03-16	2001-09-04	株式会社東海理化電機製作所	ウエビング巻取装置
US7563874B2 (en) *	1998-08-31	2009-07-21	The Regents Of The University Of California	Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
MXPA06011199A (es) *	2004-03-31	2007-04-16	Genentech Inc	Anticuerpos anti-tgf-beta humanizados.
EP1850873B1 (en) *	2005-02-08	2018-11-28	Genzyme Corporation	Antibodies to tgfbeta
MX2009003518A (es) *	2006-10-03	2009-08-25	Genzyme Corp	Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
ATE554791T1 (de)	2007-02-23	2012-05-15	Schering Corp	Gentechnisch hergestellte anti-il-23p19- antikörper
EP2064242A1 (en)	2007-02-23	2009-06-03	Schering Corporation	Engineered anti-il-23p19 antibodies
US8598321B2 (en)	2007-03-22	2013-12-03	The Regents Of The University Of California	Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2010014854A2 (en)	2008-07-31	2010-02-04	The Regents Of The University Of California	Antibodies that neutralize botulinum neurotoxins
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
NZ621170A (en)	2009-05-13	2015-08-28	Genzyme Corp	Anti-human cd52 immunoglobulins
EA201892184A1 (ru)	2010-03-01	2019-03-29	БАЙЕР ХЕЛЬСКЕР ЛЛСи	Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
SI2835053T1 (sl)	2010-03-12	2016-09-30	Genzyme Corporation	Kombinirana terapija za zdravljenje raka dojke
US9243057B2 (en)	2010-08-31	2016-01-26	The Regents Of The University Of California	Antibodies for botulinum neurotoxins
MY165160A (en) *	2010-09-01	2018-02-28	Genzyme Corp	TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
JP2014505666A (ja)	2010-11-18	2014-03-06	ザジェネラルホスピタルコーポレイション	癌治療のための降圧剤の組成物および使用
CA2818548A1 (en)	2010-11-19	2012-05-24	Toshio Imai	Neutralizing anti-ccl20 antibodies
MY171135A (en)	2011-06-03	2019-09-27	Xoma Technology Ltd	Antibodies specific for tgf-beta
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en)	2011-10-26	2016-05-12	Seattle Children's Research Institute	Cysteamine in the treatment of fibrotic disease
US9782452B2 (en)	2011-11-22	2017-10-10	Cornell University	Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US9518112B2 (en)	2012-03-08	2016-12-13	Ludwig Institute For Cancer Research Ltd	TGF-β1 specific antibodies and methods and uses thereof
EP2822871A4 (en)	2012-03-08	2015-12-09	Selig Sealing Products Inc	TANK SEALING ELEMENT WITH A PROTECTED SAFETY COMPONENT AND A REMOVAL BAG
BR112015021595A2 (pt)	2013-03-11	2017-10-10	Genzyme Corp	anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
CN105358677B (zh)	2013-03-14	2018-06-15	布里格海姆妇女医院公司	用于上皮干细胞扩增和培养的组合物和方法
US9598486B2 (en)	2013-03-20	2017-03-21	Genzyme Corporation	Methods for treating osteogenesis imperfecta
AU2014262843B2 (en)	2013-05-06	2017-06-22	Scholar Rock, Inc.	Compositions and methods for growth factor modulation
HK1225740A1 (zh)	2013-08-22	2017-09-15	Acceleron Pharma Inc.	TGF-β受体II型变体及其用途
KR102360315B1 (ko) *	2014-05-16	2022-02-08	웰헤드 바이오로지컬 테크놀로지 코포레이션.	신장 섬유증을 억제하기 위한 진세노사이드 m1의 용도
KR102493376B1 (ko)	2014-09-03	2023-01-27	더 브리검 앤드 우먼즈 하스피털, 인크.	청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh)	2014-10-14	2022-08-19	诺华股份有限公司	针对pd-l1的抗体分子及其用途
SI3240805T1 (sl)	2014-12-15	2025-04-30	The Regents Of The University Of California	Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
US11384350B2 (en)	2014-12-15	2022-07-12	The Regents Of The University Of California	Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
GB2557389B (en)	2015-01-14	2020-12-23	Brigham & Womens Hospital Inc	Treatment of cancer with anti-lap monoclonal antibodies
EP3277716B1 (en)	2015-04-03	2020-06-24	XOMA Technology Ltd.	Treatment of cancer using inhibitors of tgf-beta and pd-1
US10723793B2 (en)	2015-06-12	2020-07-28	Ludwig Institute For Cancer Research, Ltd.	TGF-β3 specific antibodies and methods and uses thereof
TW201718010A (zh) *	2015-06-19	2017-06-01	健臻公司	治療原發性局部節段性腎小球硬化症之方法
EP3316902A1 (en)	2015-07-29	2018-05-09	Novartis AG	Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
PL3317301T3 (pl)	2015-07-29	2021-11-15	Novartis Ag	Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3331550B1 (en)	2015-08-04	2022-11-02	Acceleron Pharma Inc.	Composition for treating myeloproliferative disorders
SMT202300027T1 (it) *	2015-10-30	2023-05-12	Univ California	Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso
JP2019503349A (ja)	2015-12-17	2019-02-07	ノバルティスアーゲー	Ｐｄ−１に対する抗体分子およびその使用
EP3389720A1 (en)	2015-12-18	2018-10-24	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
CA3010610A1 (en)	2016-01-08	2017-07-13	The Brigham And Women's Hospital, Inc.	Production of differentiated enteroendocrine cells and insulin producing cells
EP3405475B1 (en) *	2016-01-21	2022-09-28	The Scripps Research Institute	Synthetic opioid vaccine
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
JP2019509737A (ja)	2016-03-11	2019-04-11	スカラーロックインコーポレイテッドＳｃｈｏｌａｒＲｏｃｋ，Ｉｎｃ．	ＴＧＦβ１結合性免疫グロブリンおよびその使用
WO2017201036A1 (en)	2016-05-17	2017-11-23	Genentech, Inc.	Stromal gene signatures for diagnosis and use in immunotherapy
GB201610044D0 (en) *	2016-06-08	2016-07-20	Ucb Biopharma Sprl	Antibodies
WO2018027329A1 (en) *	2016-08-11	2018-02-15	Precithera, Inc.	TGF-β ANTAGONIST CONJUGATES
US11701384B2 (en)	2016-09-02	2023-07-18	The Regents Of The University Of California	Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
TW201811827A (zh) *	2016-09-05	2018-04-01	日商中外製藥股份有限公司	抗ＴＧＦ－β１抗體及使用方法
WO2018106931A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
CN110392686A (zh)	2016-12-30	2019-10-29	频率治疗公司	1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
US20180207267A1 (en)	2017-01-06	2018-07-26	Scholar Rock, Inc.	Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
TW202421659A (zh) *	2017-01-20	2024-06-01	美商健臻公司	骨靶向抗體
TWI856437B (zh)	2017-01-20	2024-09-21	法商賽諾菲公司	抗TGF-β抗體及其用途
EP3571227A1 (en)	2017-01-20	2019-11-27	Sanofi	Anti-tgf-beta antibodies and their use
SI3628049T1 (sl)	2017-05-04	2023-10-30	Acceleron Pharma Inc.	Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
KR20200021087A (ko)	2017-06-22	2020-02-27	노파르티스 아게	Cd73에 대한 항체 분자 및 이의 용도
WO2019075090A1 (en)	2017-10-10	2019-04-18	Tilos Therapeutics, Inc.	ANTI-LAP ANTIBODIES AND USES THEREOF
JP7544597B2 (ja)	2017-11-06	2024-09-03	ジェネンテック，インコーポレイテッド	がんの診断及び療法
RU2020119578A (ru)	2017-11-16	2021-12-17	Новартис Аг	Комбинированные терапии
SG11202005005YA (en)	2017-11-30	2020-06-29	Novartis Ag	Bcma-targeting chimeric antigen receptor, and uses thereof
TWI823906B (zh)	2018-03-09	2023-12-01	美商艾吉納斯公司	抗-cd73 抗體及其使用方法
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
JP7398396B2 (ja)	2018-06-01	2023-12-14	ノバルティスアーゲー	Ｂｃｍａに対する結合分子及びその使用
US12227565B2 (en)	2018-06-20	2025-02-18	Biora Therapeutics, Inc.	Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN112703038B (zh) *	2018-07-10	2025-07-29	赛诺菲	靶向CD38和TGF-β的抗癌组合疗法
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
TW202019957A (zh)	2018-07-11	2020-06-01	美商供石公司	TGFβ1抑制劑及其用途
US12252531B2 (en)	2018-07-11	2025-03-18	Scholar Rock, Inc.	Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
DK3677278T3 (da)	2018-07-11	2022-01-10	Scholar Rock Inc	Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
AU2019321641A1 (en)	2018-08-17	2021-04-15	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by upregulating Jag-1
US11617745B2 (en)	2018-08-17	2023-04-04	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating FOXO
CA3108949A1 (en)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
JP7407822B2 (ja)	2018-08-30	2024-01-04	エイチシーダブリューバイオロジックスインコーポレイテッド	単鎖キメラポリペプチドおよびその使用
JP2022504839A (ja)	2018-10-10	2022-01-13	ティロス・セラピューティクス・インコーポレイテッド	抗ｌａｐ抗体変異体及びその使用
AU2019375036A1 (en)	2018-11-05	2021-06-03	Centre Hospitalier Universitaire Vaudois	Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof
CA3118027A1 (en)	2018-11-05	2020-05-14	Ludwig Institute For Cancer Research Ltd.	Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof
CN116726361A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
CN113271945A (zh)	2018-12-20	2021-08-17	诺华股份有限公司	包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
MX2021009175A (es)	2019-01-30	2021-09-14	Scholar Rock Inc	Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
EP3924055B1 (en)	2019-02-15	2024-04-03	Novartis AG	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (ja)	2019-02-15	2024-05-15	ノバルティスアーゲー	３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020257639A1 (en)	2019-06-21	2020-12-24	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
CA3152371A1 (en)	2019-08-01	2021-02-04	Vaccinex, Inc.	Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
BR112022007749A2 (pt)	2019-10-23	2022-07-05	Cue Biopharma Inc	Construto de tgf-b, mascarado, complexo de tgf-b, heterodímero do complexo de tgf-b mascarado, um ou mais ácidos nucleicos, uso de um ou mais construtos ou complexos de tgf-b mascarados, composição, método de produção de um construto ou complexo de tgf-b mascarado e composição farmacêutica
US11707610B2 (en)	2019-12-13	2023-07-25	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
TW202135859A (zh)	2019-12-20	2021-10-01	瑞士商諾華公司	組合療法
MX2022008609A (es)	2020-01-11	2022-11-10	Scholar Rock Inc	Inhibidores de tgf¿ y uso de los mismos.
US12187763B2 (en)	2020-02-11	2025-01-07	Immunitybio, Inc.	Chromatography resin and uses thereof
WO2021163369A2 (en)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methods of treating age-related and inflammatory diseases
CA3169243A1 (en)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methods of activating regulatory t cells
WO2021188749A1 (en)	2020-03-19	2021-09-23	Genentech, Inc.	Isoform-selective anti-tgf-beta antibodies and methods of use
JP7734693B2 (ja)	2020-04-29	2025-09-05	イミュニティーバイオインコーポレイテッド	抗ｃｄ２６タンパク質及びそれらの使用法
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
KR20230027056A (ko)	2020-06-23	2023-02-27	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
WO2022043557A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
US20230338587A1 (en)	2020-08-31	2023-10-26	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
IL302569A (en)	2020-11-06	2023-07-01	Novartis Ag	Cd19 binding molecules and uses thereof
KR20230118573A (ko) *	2020-11-11	2023-08-11	에이치큐 한	액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도
WO2022115611A1 (en)	2020-11-25	2022-06-02	Catamaran Bio, Inc.	Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4284510A1 (en)	2021-01-29	2023-12-06	Novartis AG	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
KR20230146032A (ko)	2021-02-15	2023-10-18	다케다 야쿠힌 고교 가부시키가이샤	Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
US12180521B2 (en)	2021-02-19	2024-12-31	Theripion, Inc.	Paraoxonase fusion polypeptides and related compositions and methods
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN112940119B (zh) *	2021-04-26	2022-05-20	北京芳渟阳生生物科技有限公司	一种单克隆抗体及其与间充质干细胞外泌体的联合应用
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
WO2022256723A2 (en)	2021-06-03	2022-12-08	Scholar Rock, Inc.	Tgf-beta inhibitors and therapeutic use thereof
EP4384200A1 (en)	2021-08-11	2024-06-19	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
WO2023080900A1 (en)	2021-11-05	2023-05-11	Genentech, Inc.	Methods and compositions for classifying and treating kidney cancer
WO2023201310A1 (en)	2022-04-13	2023-10-19	HCW Biologics, Inc.	Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
AU2023254210A1 (en)	2022-04-13	2024-10-03	Immunitybio, Inc.	Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
TWI866210B (zh)	2022-05-17	2024-12-11	大陸商蘇州創勝醫藥集團有限公司	雙功能蛋白質及其製劑和用途
WO2024077095A1 (en)	2022-10-05	2024-04-11	Genentech, Inc.	Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en)	2022-10-05	2024-04-11	Genentech, Inc.	Methods and compositions for classifying and treating lung cancer
WO2024149237A1 (zh) *	2023-01-09	2024-07-18	北京拓界生物医药科技有限公司	TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
EP4509522A1 (en)	2023-08-16	2025-02-19	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same
WO2025058919A1 (en) *	2023-09-12	2025-03-20	Lyell Immunopharma, Inc.	Bispecific chimeric antigen receptors and use thereof
WO2025140212A1 (en) *	2023-12-26	2025-07-03	Laekna Therapeutics Shanghai Co., Ltd.	Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2056642B (en)	1979-08-08	1983-05-11	Dawson Int	Radio frequency drying of textile material
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US20040028682A1 (en) *	1989-09-29	2004-02-12	Border Wayne A.	Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1992010423A1 (en)	1990-12-10	1992-06-25	Panama Engineering Pty Limited	Fork-lift attachment
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
US5565332A (en) *	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
US5269388A (en)	1991-11-12	1993-12-14	Stress-Tek, Inc.	Weighing bed
US5543143A (en) *	1992-03-06	1996-08-06	Corixa Corporation	Method for activating macrophages/monocytes
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5824655A (en)	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
DK0929578T3 (da)	1996-02-09	2003-08-25	Abbott Lab Bermuda Ltd	Humane antistoffer, der binder human TNFalfa
DE69738962D1 (de)	1996-03-10	2008-10-16	Meiji Dairies Corp	Auf peptiden basierendes immunotherapeutisches mittel gegen allergien
DE69941267D1 (de)	1998-12-10	2009-09-24	Bristol Myers Squibb Co	Proteingerüste für antikörper-nachahmer und andere bindende proteine
KR20120091477A (ko) *	1999-03-25	2012-08-17	애보트 게엠베하 운트 콤파니 카게	사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
NZ521182A (en)	2000-03-03	2004-11-26	Cambridge Antibody Tech	Human antibodies against eotaxin comprising VH adn VL domains and their use
US20030224501A1 (en) *	2000-03-17	2003-12-04	Young Paul E.	Bone morphogenic protein polynucleotides, polypeptides, and antibodies
YU45103A (sh) *	2000-12-06	2006-08-17	Applied Research Systems Ars Holding N.V.	Upotreba sarp/1 za lečenje i prevenciju skleroderme
KR100942073B1 (ko) *	2002-08-23	2010-02-12	기린 홀딩스 가부시키가이샤	ＴＧＦ β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물
EP1620128A1 (en) *	2003-04-30	2006-02-01	Genzyme Corporation	Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en)	2003-07-09	2005-02-03	Eli Lilly And Company	Tgf-beta1 ligands
GB0407315D0 (en) *	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
JP2005112812A (ja) *	2003-10-09	2005-04-28	Zeria Pharmaceut Co Ltd	リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
DK1702059T3 (da)	2003-12-09	2013-03-04	Novozymes Inc	Fremgangsmåder til eliminering og reduktion af ekspression af gener i filamentøse svampestammer
MXPA06011199A (es) *	2004-03-31	2007-04-16	Genentech Inc	Anticuerpos anti-tgf-beta humanizados.
KR100749566B1 (ko) *	2004-04-21	2007-08-16	이화여자대학교 산학협력단	Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
EP1850873B1 (en) *	2005-02-08	2018-11-28	Genzyme Corporation	Antibodies to tgfbeta
ITMI20110376A1 (it)	2011-03-10	2012-09-11	Wilic Sarl	Aerogeneratore raffreddato a fluido
DE102011078333A1 (de)	2011-06-29	2013-01-03	Siemens Aktiengesellschaft	Überspannungsableiter

2006
- 2006-02-08 EP EP06734583.5A patent/EP1850873B1/en active Active
- 2006-02-08 CA CA2930677A patent/CA2930677A1/en not_active Abandoned
- 2006-02-08 PT PT182083824T patent/PT3520815T/pt unknown
- 2006-02-08 AU AU2006213875A patent/AU2006213875B2/en active Active
- 2006-02-08 CN CNA2006800088389A patent/CN101163502A/zh active Pending
- 2006-02-08 DK DK06734583.5T patent/DK1850873T3/en active
- 2006-02-08 CN CN201410332384.7A patent/CN104151427B/zh active Active
- 2006-02-08 PT PT06734583T patent/PT1850873T/pt unknown
- 2006-02-08 SI SI200632315T patent/SI1850873T1/sl unknown
- 2006-02-08 ES ES06734583T patent/ES2711213T3/es active Active
- 2006-02-08 LT LTEP06734583.5T patent/LT1850873T/lt unknown
- 2006-02-08 PL PL18208382T patent/PL3520815T3/pl unknown
- 2006-02-08 PL PL06734583T patent/PL1850873T3/pl unknown
- 2006-02-08 CA CA2597098A patent/CA2597098C/en active Active
- 2006-02-08 WO PCT/US2006/004424 patent/WO2006086469A2/en not_active Ceased
- 2006-02-08 CN CN201410331821.3A patent/CN104177497B/zh active Active
- 2006-02-08 EP EP18208382.4A patent/EP3520815B1/en active Active
- 2006-02-08 HU HUE06734583A patent/HUE042689T2/hu unknown
- 2006-02-08 JP JP2007554339A patent/JP5174466B2/ja active Active
- 2006-02-08 TR TR2019/01929T patent/TR201901929T4/tr unknown
- 2006-02-08 MX MX2007009545A patent/MX2007009545A/es active IP Right Grant
- 2006-02-08 BR BRPI0607639-4A patent/BRPI0607639B1/pt active IP Right Grant
- 2006-02-08 ES ES18208382T patent/ES2905923T3/es active Active
- 2006-02-08 US US11/350,906 patent/US7723486B2/en active Active
2007
- 2007-01-30 US US11/700,684 patent/US20070264255A1/en not_active Abandoned
- 2007-01-30 US US11/700,711 patent/US20070134246A1/en not_active Abandoned
- 2007-08-02 IL IL184995A patent/IL184995A/en active IP Right Grant
2010
- 2010-03-15 US US12/724,347 patent/US8383780B2/en active Active
2012
- 2012-08-16 JP JP2012180580A patent/JP5726140B2/ja active Active
- 2012-09-13 US US13/615,388 patent/US8591901B2/en active Active
2013
- 2013-04-14 IL IL225752A patent/IL225752A/en active IP Right Grant
- 2013-10-21 US US14/059,241 patent/US9090685B2/en active Active
2014
- 2014-09-22 JP JP2014192304A patent/JP6005703B2/ja active Active
2015
- 2015-04-09 US US14/682,975 patent/US9481726B2/en active Active
2016
- 2016-03-30 JP JP2016067713A patent/JP6341945B2/ja active Active
- 2016-09-28 US US15/278,819 patent/US10174108B2/en active Active
2017
- 2017-08-01 JP JP2017148818A patent/JP6463807B2/ja active Active
- 2017-10-16 IL IL255078A patent/IL255078B/en active IP Right Grant
2018
- 2018-11-21 US US16/197,802 patent/US10781252B2/en active Active
2019
- 2019-02-26 CY CY20191100235T patent/CY1121424T1/el unknown
2020
- 2020-08-19 US US16/997,365 patent/US20210061897A1/en not_active Abandoned
2022
- 2022-09-16 US US17/932,950 patent/US20230078449A1/en active Pending

Also Published As

Publication number	Publication date
ES2711213T3 (es)	2019-04-30
JP5174466B2 (ja)	2013-04-03
JP6341945B2 (ja)	2018-06-13
EP1850873B1 (en)	2018-11-28
WO2006086469A2 (en)	2006-08-17
SI1850873T1 (sl)	2019-05-31
MX2007009545A (es)	2008-03-11
PT3520815T (pt)	2022-02-02
US7723486B2 (en)	2010-05-25
US10781252B2 (en)	2020-09-22
JP2013031444A (ja)	2013-02-14
EP3520815B1 (en)	2021-11-17
LT1850873T (lt)	2019-04-10
HK1201860A1 (en)	2015-09-11
JP6005703B2 (ja)	2016-10-12
HUE042689T2 (hu)	2019-07-29
PL1850873T3 (pl)	2019-06-28
CN104151427A (zh)	2014-11-19
BRPI0607639A2 (pt)	2009-09-22
US20130243788A1 (en)	2013-09-19
EP1850873A4 (en)	2012-06-13
IL184995A (en)	2013-04-30
US20070264255A1 (en)	2007-11-15
IL225752A0 (en)	2013-06-27
US8383780B2 (en)	2013-02-26
JP6463807B2 (ja)	2019-02-06
CA2930677A1 (en)	2006-08-17
US9090685B2 (en)	2015-07-28
IL184995A0 (en)	2007-12-03
US20230078449A1 (en)	2023-03-16
PL3520815T3 (pl)	2022-04-11
JP2008529503A (ja)	2008-08-07
US20210061897A1 (en)	2021-03-04
US20060251658A1 (en)	2006-11-09
WO2006086469A3 (en)	2007-04-19
US10174108B2 (en)	2019-01-08
US20150284456A1 (en)	2015-10-08
US20190177406A1 (en)	2019-06-13
US20110008364A1 (en)	2011-01-13
US9481726B2 (en)	2016-11-01
US20170066821A1 (en)	2017-03-09
AU2006213875A1 (en)	2006-08-17
US20070134246A1 (en)	2007-06-14
CA2597098A1 (en)	2006-08-17
US20140127230A1 (en)	2014-05-08
EP3520815A1 (en)	2019-08-07
JP2015003917A (ja)	2015-01-08
IL225752A (en)	2017-10-31
IL255078A0 (en)	2017-12-31
ES2905923T3 (es)	2022-04-12
CN104177497B (zh)	2018-01-16
JP2017217003A (ja)	2017-12-14
EP1850873A2 (en)	2007-11-07
BRPI0607639B1 (pt)	2022-04-05
JP5726140B2 (ja)	2015-05-27
US8591901B2 (en)	2013-11-26
CN104151427B (zh)	2017-09-08
TR201901929T4 (tr)	2019-03-21
IL255078B (en)	2021-01-31
DK1850873T3 (en)	2019-03-18
HK1201859A1 (en)	2015-09-11
CA2597098C (en)	2016-08-02
CN101163502A (zh)	2008-04-16
CN104177497A (zh)	2014-12-03
CY1121424T1 (el)	2020-05-29
AU2006213875B2 (en)	2010-08-19
JP2016128512A (ja)	2016-07-14

Publication	Publication Date	Title
PT1850873T (pt)	2019-02-19	Anticorpos contra tgfbeta
IL189599A0 (en)	2008-08-07	Methods to enhance chemotherapy
IL191340A (en)	2015-08-31	Monoclonal antibodies against e8o
IL186739A0 (en)	2008-02-09	Antibodies to myostatin
ZA200900395B (en)	2010-01-27	Antibodies directed to +-Vß6 and uses thereof
IL187106A (en)	2015-10-29	Sclerostin binds antibody
IL190472A0 (en)	2008-11-03	Anti-glypican-3 antibody
ZA200805850B (en)	2009-04-29	Anti-ILT7 antibody
IL185366A0 (en)	2008-02-09	Antibody
EP2125890A4 (en)	2010-04-07	ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
PL2011869T3 (pl)	2014-11-28	Nowe przeciwciało anty-CD98
GB0517487D0 (en)	2005-10-05	Antibodies
EP1869192A4 (en)	2010-10-20	FRAME MIXTURE OF ANTIBODIES
IL172276A0 (en)	2006-04-10	Cross-reference to related application
EP1896047A4 (en)	2009-07-22	ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en)	2005-04-20	Antibodies
ZA200804254B (en)	2009-01-28	Human monoclonal antibodies to O8E
GB0505054D0 (en)	2005-04-20	Antibodies
GB0512278D0 (en)	2005-07-27	Antibodies
GB0517718D0 (en)	2005-10-05	Further improvement to brikmat
GB2423802B (en)	2009-05-06	Improvements relating to vacuum-brake-boosters
GB0500847D0 (en)	2005-02-23	Claims to be made
GB0519883D0 (en)	2005-11-09	Antibodies
GB0413163D0 (en)	2004-07-14	Improvements to signware
GB0500400D0 (en)	2005-02-16	Antibody